Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): Results from a prospective multi-center study.

Saved in:

Bibliographic Details
Journal Title:	Journal of Clinical Oncology
Authors and Corporations:	Unseld, Matthias, Kornek, Gabriele, Gleiss, Andreas, Demyantes, Svitlana, Schwarzwald, Jost, Bianconi, Daniela, Andel, Johannes, Tinchon, Christoph, Pecherstorfer, Martin, Eisterer, Wolfgang, Jagdt, Björn, Kretschmer, Andreas, Gerger, Armin, Greil, Richard, Seebacher, Adelheid, Krippl, Peter, Laengle, Friedrich, Zielinski, Christoph, Scheithauer, Werner, Prager, Gerald W.
In:	Journal of Clinical Oncology, 35, 2017, 4_suppl, p. 604-604
Type of Resource:	E-Article
Language:	English
published:	American Society of Clinical Oncology (ASCO)
Subjects:	Cancer Research Oncology

Internet